Healthcare Providers and Services
Company Overview of ARUP Laboratories, Inc.
ARUP Laboratories, Inc. operates a clinical and anatomic pathology reference laboratory in the United States. It offers ATOP, a laboratory analytics service to identify over-, under-, and mis-utilization of individual laboratory tests; ARUP Connect, an online information system for referral test management that enables to access test results, submit statistical data, and retrieve files; and ARUP Consult, a guide on PDA and Web platforms to assist the clinician with laboratory test selection and interpretation. The company also provides ARUP Direct, a start-to-finish outreach program to help clients; ARUP Gateway, an integrated customer test menu tool to serve the client's outreach medical co...
500 Chipeta Way
Salt Lake City, UT 84108-1221
Founded in 1984
Key Executives for ARUP Laboratories, Inc.
Chief Operating Officer and Executive Vice President of Corporate Communications
Senior Technical Vice President, Medical Director of Immunology & Infectious Disease Laboratory and Executive Director
Administrative Vice President and Medical Director of Animal Reference Pathology Laboratory
Senior Vice President and Director of Marketing
Compensation as of Fiscal Year 2016.
ARUP Laboratories, Inc. Key Developments
ARUP Laboratories Appoints Edgar Braendle as CEO Effective August 16, 2016
Jul 7 16
ARUP Laboratories announced that Edgar Braendle, MD, PhD, has been named CEO, effective August 16, 2016. Throughout the search process, Dean Li, MD, PhD, has served as interim CEO, ensuring a smooth transition in leadership. Prior to joining ARUP, Braendle held multiple leadership roles at Novartis Pharmaceutical Corporation and Schering AG. Most recently, he was senior vice president and global head of Companion Diagnostics at Novartis.
ARUP Laboratories and the Children's Hospital of Philadelphia Form Partnership to Offer High-Resolution HLA Genotyping by Next Generation Sequencing
Oct 8 14
ARUP Laboratories announced that they will be offering high-resolution HLA genotyping by next generation sequencing (NGS) under an agreement with The Children's Hospital of Philadelphia (CHOP). HLA genotyping is used for identifying the best recipient/donor match combination prior to hematopoietic stem cell transplantation (HSCT). HLA genes are the most polymorphic gene family found in the entire human genome, with more than 10,000 different HLA alleles reported so far. Currently, the standard of care for HLA genotyping to select a donor for HSCT is to use a low/intermediate resolution SSO/SSP test first and then reflex the candidates to confirmatory Sanger Sequence Based Typing (SBT) to obtain higher resolution allele information to finalize the matched donor. Sanger SBT produces incomplete and ambiguous results by analyzing only sections of the HLA genes and failing to distinguish among different alleles due to difficulty with resolving cis/trans chromosomal positions of those alleles. NGS is able to overcome the limitations of Sanger SBT by performing large number of long clonal sequencing reactions, allowing reporting of complete and unambiguous HLA genotyping results.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries